Top Medical News
2 days ago
Non-alcoholic fatty liver disease (NAFLD) – a clinicopathological spectrum comprising hepatic steatosis or non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) – is the hepatic manifestation of metabolic syndrome recognized as a leading cause of liver morbidity and mortality. Dr Loo Wai Mun, Consultant at the Division of Gastroenterology and Hepatology, National University Hospital, Singapore, speaks with Audrey Abella to discuss how NAFLD can be best managed in primary care.
11 Apr 2019
Among type 2 diabetes mellitus patients without clear alcohol consumption behaviours, there is an inverse correlation between insulin-like growth factor (IGF)-1 and markers of liver fibrosis, a recent study has found.
06 Apr 2019
Despite the relative commonness of nonalcoholic fatty liver disease (NAFLD) in children with obesity, the two conditions do not occur concomitantly, a recent study suggests.
Jairia Dela Cruz, 03 Apr 2019
The use of glecaprevir plus pibrentasvir appears to be safe and highly effective in the treatment of chronic hepatitis C virus (HCV) infection genotypes 1–3 in patients with severe renal impairment, including those undergoing haemodialysis, as shown in a recent study from Japan.
31 Mar 2019
Although stroke occurs rarely in cirrhotic patients, liver cirrhosis is associated with an elevated risk of developing subarachnoid or intracranial haemorrhage, a recent meta-analysis has shown.
27 Mar 2019
In elderly adults with pneumonia, cirrhosis appears to be correlated with mortality and rehospitalization, a new study has found.
25 Mar 2019
The use of direct-acting antivirals to treat hepatitis C virus (HCV) infection appears to also reduce the risk of cardiovascular disease events, a recent study has found.
Special Reports
04 Dec 2017
Management of locally advanced hepatocellular carcinoma aims to improve survival and to maintain the quality of life of patients, with less likelihood of cure due to the advanced nature of disease. Upon diagnosis of the severity of liver cancer, offering appropriate and proven treatment options is important to extend the survival of these patients.
14 Dec 2016
At the recent Annual Scientific Congress of the Malaysian Society of Gastroenterology and Hepatology (GUT 2016), held at Shangri-La Hotel, Kuala Lumpur, an expert from Hong Kong spoke on the role of direct-acting antivirals as well as pan-genotypic agents that are set to revolutionize hepatitis C treatment.
01 Dec 2016
An expert panel meeting on hepatorenal syndrome (HRS) was recently convened in Kuala Lumpur with the aim of discussing management practices in different hospital settings. Chaired by Professor Sanjiv Mahadeva, consultant gastroenterologist, University Malaya Medical Centre, the meeting saw local and regional experts share HRS cases they have encountered in their practice.
Conference Reports
Christina Lau, 22 Feb 2018

Cabozantinib, an oral inhibitor of multiple tyrosine kinases, significantly improves overall survival (OS) and progression-free survival (PFS) in patients with advanced hepatocellular carcinoma (HCC) whose disease progressed following sorafenib or other systemic therapies.

Roshini Claire Anthony, 19 Feb 2018

Pembrolizumab demonstrated promising results in several outcomes among patients with advanced hepatocellular carcinoma (HCC) whose disease progressed on or who were unable to tolerate treatment with sorafenib, findings from the KEYNOTE-224* trial show.

Jackey Suen, 25 Oct 2017

Eradication of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection is becoming achievable, although much work still has to be done, says an expert.

Jackey Suen, 24 Oct 2017

Virtual hepatic venous pressure gradient (vHVPG), a novel noninvasive approach to assess portal hypertension, is shown to correlate well with the gold-standard invasive method in a recent Chinese study.

04 Oct 2017
Slideshow: Highlights from the Asia Pacific Digestive Week 2017 (APDW 2017)
Naomi Rodrig, 03 Oct 2017

An index of three liver-specific microRNAs (the MiR-B Index) could serve as a biomarker of spontaneous or treatment-induced transition from active to inactive chronic hepatitis B virus (HBV) infection, facilitating disease monitoring and testing of new antivirals, according to Dr Mauricia Brunetto from the University of Pisa, Italy, who spoke recently at the Asian Pacific Digestive Week (APDW) 2017 in Hong Kong.

Christina Lau, 03 Oct 2017

A new technology involving the use of monocyte-derived hepatocyte-like (MH) cells has demonstrated high sensitivity and specificity in the diagnosis of idiosyncratic drug-induced liver injury (DILI), data presented at the Asian Pacific Digestive Week (APDW) 2017 held in Hong Kong have shown.

CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download